Novo Nordisk v. Rio Biopharmaceuticals: Saxenda ANDA Dispute Dismissed Without Prejudice
Novo Nordisk filed a Hatch-Waxman infringement action in the District of New Jersey against Rio Biopharmaceuticals, asserting 17 patents covering its Saxenda liraglutide injection to block Rio’s ANDA No. 218240. The parties resolved the dispute within 225 days, with all claims dismissed without prejudice and each side bearing its own costs.
A 17-patent Hatch-Waxman fortress dissolved in under eight months
On 5 February 2024, Novo Nordisk A/S filed suit in the U.S. District Court for the District of New Jersey against Rio Biopharmaceuticals, Inc., asserting 17 U.S. patents covering its Saxenda liraglutide solution for injection (18 mg/3 ml, 6 mg/ml). The action was triggered by Rio’s submission of ANDA No. 218240 with Paragraph IV certifications, which under the Hatch-Waxman Act constitutes an act of infringement and automatically opens a 30-month stay on FDA approval.
The case closed on 17 September 2024 — just 225 days after filing — when the parties filed a joint stipulation of dismissal without prejudice approved by the court. All claims, counterclaims, and affirmative defenses were terminated. Critically, the order explicitly preserves Rio’s right to maintain its Paragraph IV certifications and does not block the FDA from granting final approval of the Rio ANDA, suggesting the resolution did not include a full capitulation by Rio.
Resolution within the 30-month stay period is commercially significant: Novo Nordisk avoided a full merits adjudication, while Rio preserved its ANDA pathway. The absence of prejudice and the silence on any licensing or market-entry date in the public record leaves open whether a private settlement agreement governs Rio’s future launch timing. The dismissal-without-prejudice mechanism means Novo Nordisk retains the right to re-file if Rio pursues FDA approval in a manner Novo Nordisk considers infringing.
Filing to Dismissed without Prejudice in 225 days
225 days — resolved well within the standard 30-month Hatch-Waxman stay window
Dismissed without prejudice: what the stipulated order means for both parties
Dismissal without prejudice preserves Novo Nordisk’s future enforcement rights
A dismissal without prejudice terminates the current action but does not bar the plaintiff from refiling. Under Federal Rule of Civil Procedure 41, Novo Nordisk retains the right to assert these 17 patents again if Rio’s conduct triggers a new cause of action — for example, upon FDA approval and a commercial launch. The court also expressly retained jurisdiction to resolve future disputes arising from this action.
Rights preserved for both partiesNovo Nordisk keeps its patent estate intact with no adverse merits ruling
No claim of the 17 asserted patents was invalidated, disclaimed, or adjudicated unenforceable. The stipulated dismissal contains no admission of non-infringement by Novo Nordisk and no validity concession. The patents continue to list in the FDA Orange Book against Saxenda, maintaining their legal presumption of validity. Novo Nordisk’s enforcement posture against other ANDA filers is unaffected by this resolution.
Patent validity uncontestedRio retains its ANDA and Paragraph IV certification — launch pathway open
The stipulated order explicitly states that nothing prevents Rio from maintaining its Paragraph IV certification or the FDA from granting final approval of ANDA No. 218240. Rio did not surrender its challenge to the patents-at-issue. Whether a confidential settlement agreement governs Rio’s market-entry date cannot be determined from the public record, but Rio’s regulatory pathway is formally intact and its legal position was not adjudicated against it.
ANDA No. 218240 remains activeEarly resolution within the 30-month stay signals negotiated rather than litigated outcome
Resolution in 225 days — before the 30-month Hatch-Waxman stay would have expired — is consistent with a negotiated agreement rather than a full-merits trial. For the GLP-1 receptor agonist sector, this pattern suggests the 17-patent portfolio around Saxenda creates meaningful settlement leverage. Other ANDA filers in the liraglutide space should monitor any undisclosed launch-date terms that may emerge if Rio seeks final FDA approval.
GLP-1 ANDA landscape watchFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Pharmaceutical innovator — holder of 17 patents covering Saxenda liraglutide injectionSearch in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Rio Biopharmaceuticals, Inc. | Company | Generic pharmaceutical company seeking FDA approval of liraglutide 6 mg/ml injection via ANDA No. 218240Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Arnold B. Calmann | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine Ann Escanlar | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is carefully worded to achieve a neutral termination: all claims are extinguished without prejudice, no party admits liability, and the court retains jurisdiction. The explicit carve-out preserving Rio’s Paragraph IV certification and FDA approval pathway is non-standard and commercially material — it confirms Rio did not concede infringement or abandon its generic entry ambitions. The absence of any reference to licensing terms or market-entry dates in the public order is consistent with confidential settlement terms governing the commercial relationship going forward.
US8114833B2 and 16 further patents — Saxenda liraglutide injection formulation and delivery
The 17 patents asserted in this action collectively protect the Saxenda liraglutide 6 mg/ml injection franchise across multiple dimensions: stable pharmaceutical formulations, injection device design and cartridge delivery, dosing regimens, and GLP-1 analog composition claims. Application filing dates span from US11/435977 (mid-2000s era) through to US16/589566, reflecting a layered prosecution strategy that extends effective market exclusivity well beyond any single patent’s expiry. US RE46,363 is a reissue patent, suggesting Novo Nordisk has actively broadened or corrected claim scope post-grant.
For the GLP-1 receptor agonist sector — one of the fastest-growing therapeutic areas in pharmaceutical IP — this portfolio represents a formidable Orange Book listing. Generic entrants must either design around all 17 patents, successfully invalidate them, or negotiate entry terms with Novo Nordisk. The breadth of device, formulation, and method claims means no single IPR petition is likely to clear the path to market. Companies developing liraglutide biosimilars or follow-on GLP-1 injection products should treat this portfolio as a high-priority FTO target.
Should you run an FTO against Novo Nordisk’s Saxenda liraglutide patent portfolio?
Any pharmaceutical company developing a generic liraglutide injection, a liraglutide biosimilar, or a GLP-1 analog product in a similar delivery format should conduct a comprehensive freedom-to-operate analysis before filing an ANDA or IND. The 17 patents at issue cover not only the active compound formulation but also device delivery systems and method-of-use claims — meaning FTO must extend beyond composition claims to pen injector design and clinical dosing protocols.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the full claim sets of all 17 Saxenda patents simultaneously, flagging overlapping claims and identifying design-around opportunities. Eureka’s patent landscape visualisation also surfaces related pending applications that may issue and extend risk exposure. For R&D and regulatory teams planning a liraglutide ANDA or biosimilar programme, early FTO analysis is essential to avoid the litigation exposure Rio faced in this action.
Run a freedom-to-operate analysis on US11097063B2 to assess your product’s exposure
Run FTO in Eureka →Similar GLP-1 and liraglutide ANDA patent cases in D.N.J.
These cases share key features with this D.N.J. Hatch-Waxman dispute: GLP-1 or liraglutide technology, ANDA triggers, and multi-patent Orange Book enforcement strategies.
What this case signals for the GLP-1 and obesity drug IP landscape
Novo Nordisk’s 17-patent Hatch-Waxman strategy around Saxenda illustrates the defensive depth available to innovators in the high-value GLP-1 space.
A 17-patent ANDA wall is a litigation settlement tool, not just a trial weapon
Asserting 17 patents in a single Hatch-Waxman complaint dramatically increases the cost and complexity of a generic challenger’s invalidity and non-infringement defence. Even without reaching trial, the breadth of the portfolio typically generates sufficient uncertainty to drive pre-trial resolution — as seen here within the 30-month stay window.
Dismissal without prejudice maintains Novo Nordisk’s enforcement leverage over Rio’s future launch
By securing a without-prejudice dismissal while preserving court jurisdiction, Novo Nordisk retains the ability to reinstate infringement claims if Rio launches at any time Novo Nordisk considers unauthorised. This mechanism is strategically superior to a with-prejudice dismissal for a patent holder that may need to respond to a future FDA approval event.
A/S v Rio — key questions answered
Novo Nordisk asserted 17 U.S. patents: US8114833, US8684969, US8920383, US9108002, US9132239, US9457154, US9616180, US9687611, US9775953, US9861757, US10220155, US10357616, US10376652, US11097063, US11311679, US11446443, and USRE46363. All cover aspects of the Saxenda liraglutide 6 mg/ml injection, including formulations, delivery devices, and methods of use.
The parties filed a joint stipulated order of dismissal without prejudice on 17 September 2024, indicating they resolved the action privately. A without-prejudice dismissal means Novo Nordisk retains the right to refile if Rio pursues FDA approval in a manner Novo Nordisk considers infringing. The public record does not disclose the specific terms of any underlying settlement agreement.
No. The stipulated dismissal order explicitly provides that Rio may maintain its Paragraph IV certifications in ANDA No. 218240 and that the FDA is not prevented from granting final approval. Rio’s regulatory pathway for its generic liraglutide 6 mg/ml injection product formally remains intact following the dismissal.
Under the Hatch-Waxman Act, a branded pharmaceutical company can trigger a 30-month stay of FDA approval for a generic ANDA by filing an infringement suit within 45 days of receiving notice of a Paragraph IV certification. Novo Nordisk filed suit on 5 February 2024; the 30-month stay would have run approximately to August 2026. Resolution in 225 days — well within that window — is consistent with the parties reaching a negotiated agreement before a full merits adjudication was necessary.
Novo Nordisk was represented by Saul Ewing LLP, with attorneys Alexander Lee Callo, Charles Michael Lizza, Sarah Ann Sullivan, and William C. Baton. Rio Biopharmaceuticals was represented by Saiber LLC, with attorneys Arnold B. Calmann and Katherine Ann Escanlar.
PatSnap Eureka searches patents and litigation data to answer instantly.